SCHEMBL5164007

SCHEMBL5164007

COC(=O)c1cc(Br)cc(-c2ccc(CNS(=O)(=O)c3ccccc3OC)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
L3MBTL1 Q9Y468 1/20 0.48
FABP4 P15090 2/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 3/20 0.47
POLB P06746 1/20 0.46
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
HPGD P15428 1/20 0.43
PKM P14618 1/20 0.43
ACLY P53396 1/20 0.43
BRD4 O60885 2/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
GLA P06280 1/20 0.42
CNR1 P21554 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163905 0.81 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1FABP4LMNACYP1A2
SCHEMBL5166003 0.80 SMN1; SMN2 (0.60) SMN1; SMN2L3MBTL1FABP4LMNACYP1A2
SCHEMBL5166956 0.75 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1FABP4LMNACYP1A2
SCHEMBL119144 0.74 FABP4 (0.61) SMN1; SMN2L3MBTL1FABP4LMNACYP1A2
SCHEMBL28418982 0.72 ADORA3 (0.46) L3MBTL1POLBHPGDMAPT
SCHEMBL5167268 0.72 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1FABP4LMNACYP1A2
SCHEMBL5167263 0.72 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1FABP4LMNACYP1A2
SCHEMBL5166693 0.72 NR3C2 (0.57) SMN1; SMN2L3MBTL1LMNACYP1A2CYP2C19
SCHEMBL31078371 0.71 SMN1; SMN2 (0.77) SMN1; SMN2CYP1A2CYP2C19ALDH1A1POLB
SCHEMBL4500103 0.71 NOTUM (0.53) SMN1; SMN2ALDH1A1CA12CA9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765332-A2 TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-03-28 EP disclosed
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed
WO-2006009876-A2 TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135773-A1 Trisubstituted nitrogen modulators of tyrosine phosphatases PTPA, PTPN1, PTPRS SMN1; SMN2 3478/4885L3MBTL1 1942/4885FABP4 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.